ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Apollomics Inc

Apollomics Inc (APLM)

0.45
-0.021
(-4.46%)
Closed April 27 4:00PM
0.45
0.00
(0.00%)
After Hours: 4:37PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.45
Bid
0.45
Ask
0.469
Volume
245,270
0.4345 Day's Range 0.489
0.40 52 Week Range 6.45
Market Cap
Previous Close
0.471
Open
0.457
Last Trade
23
@
0.45
Last Trade Time
Financial Volume
$ 111,897
VWAP
0.45622
Average Volume (3m)
204,037
Shares Outstanding
86,795,840
Dividend Yield
-
PE Ratio
-0.16
Earnings Per Share (EPS)
-2.77
Revenue
1.45M
Net Profit
-240.81M

About Apollomics Inc

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell... Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Foster City, California, USA
Founded
1970
Apollomics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APLM. The last closing price for Apollomics was $0.47. Over the last year, Apollomics shares have traded in a share price range of $ 0.40 to $ 6.45.

Apollomics currently has 86,795,840 shares outstanding. The market capitalization of Apollomics is $39.06 million. Apollomics has a price to earnings ratio (PE ratio) of -0.16.

APLM Latest News

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion...

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China –...

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

FOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06-11.76470588240.510.530.43020400.47060119CS
4-0.24-34.78260869570.690.730.41916770.54164491CS
12-0.3528-43.94618834080.80280.8320.42040370.62083214CS
26-0.4199-48.26991608230.86991.790.419290810.87789328CS
52-5.21-92.04946996475.666.450.49971921.00553776CS
156-18.15-97.580645161318.6490.49492441.3216017CS
260-18.15-97.580645161318.6490.49492441.3216017CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

APLM Discussion

View Posts
Frankestin Frankestin 1 day ago
https://ir.apollomicsinc.com/news-releases/news-release-details/apollomics-announces-approval-vebreltinib-china-first-class
Important!
Whoever be short here deserves to know about this disease!
👍️0
Monksdream Monksdream 3 days ago
APLM new 52 week low
👍️0
Frankestin Frankestin 2 months ago
So enormous
Short Borrow Fee Rates
2024-02-12 638.05
👍️0
elks elks 5 months ago
Going to get in.
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 5 months ago
$APLM
https://x.com/hannahadad8890/status/1729441006372716957?s=61
👍️0
BoilerRoom BoilerRoom 5 months ago
Will check it out. Thanks
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 5 months ago
$APLM
https://x.com/hannahadad8890/status/1728985884849299629?s=61
👍️0
BoilerRoom BoilerRoom 5 months ago
Buy the crypto LCX suppose 700-1000x in 2024. All my opinion of course not financial advice. Disclaimer I purchased $50,000 worth.
👍️0
BoilerRoom BoilerRoom 5 months ago
Thanks
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 5 months ago
$APLM
https://x.com/hannahadad8890/status/1728088405362221465?s=61
👍️0
Jess070283 Jess070283 5 months ago
Huge News!
👍️0
BoilerRoom BoilerRoom 6 months ago
$APLM in at .85 for swing trade. Out of day trades. Uggggh
👍️0
TimeFades TimeFades 6 months ago
In 83
👍️0
TheFinalCD TheFinalCD 6 months ago
FILLED 1.19 FOR A BOUNCE TRADE

BIDS LOWER
👍️0
TheFinalCD TheFinalCD 6 months ago
sold 1.31 NOW HALTED DOWN 1.21

WONDER WHERE THE BOTTOM IS??
👍️0
TheFinalCD TheFinalCD 6 months ago
$APLM Overall Risk Low https://dilutiontracker.com/app/search/APLM


THE CONCERNING PART IS 394M OS
https://finviz.com/quote.ashx?t=APLM&ty=c&ta=1&p=d

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172036516&txt2find=APLM
👍️0
TheFinalCD TheFinalCD 6 months ago
APLM NHOD I FINALLY BOUGHT THE DIP

LIKE A DIP CHIT

1.13 LOWEST FILL
👍️ 1 😂 1 😅 1 🤠 1 🤣 1
TheFinalCD TheFinalCD 6 months ago
1.32 CONGRAT$ TO ANYONE MAKING $
👍️0
subslover subslover 6 months ago
Everything I learned about mathematics is now meaningless! The only way we make money now is to day trade these PUMPS and it makes no difference that most are horrid POS Companies. Forget the OTC that you and I made most of our money in over the years we have known each other that died 2 years ago
👍️0
TheFinalCD TheFinalCD 6 months ago
AGREED~! ITS SO BAD IT MAKES IT DIFFICULT TO GAUGE, READ, AND TRADE


ACTUALLY VERY DIFFICULT


APLM @ $1

LONG ?
SHORT ?
OR SIT ON HANDS ?
👍️0
subslover subslover 6 months ago
Because the entire stock market became corrupt. Sad but true!
👍️ 1
TheFinalCD TheFinalCD 6 months ago
that was yesterdays news, wondering why it was -26% on that news and hit low .52 then 1.17 today>?????

https://finviz.com/quote.ashx?t=APLM&p=d
👍️0
subslover subslover 6 months ago
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023.

The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study (NCT03175224).

“PTPRZ-MET fusions are known to cause aggressive forms of GBM and are associated with poor prognosis. We are pleased to achieve positive clinical results in patients with this deadly disease, further demonstrating the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics. “We are also pleased with the progress in our vebreltinib development programs for treating solid tumors with various MET alterations.” While the company is encouraged by the results, this information may not be indicative of efficacy in a larger GBM patient population.

GBM with MET fusion is an indication pursued by Apollomics and its China partner, Avistone Biotechnology. Avistone sponsors an active-controlled phase 2/3 study of vebreltinib for the treatment of GBM with PTPRZ-MET fusion, and has been in communication with the National Medical Products Administration (NMPA) regarding a supplemental New Drug Application (NDA) for this indication and has recently received priority review from the NMPA.

The ESMO 2023 conference presentation is available on the Apollomics website at https://ir.apollomicsinc.com/news-events/presentations.
👍️0
Disquisition Disquisition 6 months ago
UNREAL DUMPING
👍️0
Awl416 Awl416 11 months ago
Volume
👍️0
Awl416 Awl416 12 months ago
Ridiculous
👍️0
Invest-in-America Invest-in-America 1 year ago
APLM: CONGRATS, King EZ!!! You are iHub's BEST!!!!
👍️0
Invest-in-America Invest-in-America 1 year ago
APLM: That iHub crap happens all the time; don't feel alone on THAT score.
👍️0
makinezmoney makinezmoney 1 year ago
$APLM: I opened this board with SharePrice at $22

And now its up to $43


Looks like the iHUB people are shutting down my board again like previous..... and I'm running out of free posts.

This one started trading today and now its my SECOND time opening up this board. WHAT GIVES ??

https://www.apollomicsinc.com/


GO $APLM
👍️0

Your Recent History

Delayed Upgrade Clock